Perkinelmer Launches Clarus 600 Gas Chromatograph/Mass Spectrometers to Meet Wide Range of Performance, Budget Needs
Only Supplier to Develop, Manufacture, Test, Support and Service Complete Integrated System
BOSTON – August 30, 2006 – PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, has introduced the Clarus® 600 Gas Chromatograph/Mass Spectrometers (GC/MS) with best-in-class oven performance, delivering the fastest combined heat-up and cool-down rates for a conventional GC. It also provides state-of-the-art electronics, enhanced software and a choice of three different pumps to meet the diverse performance demands and budget requirements of a range of laboratories.
“The Clarus 600 GC/MS is an extremely robust, precise and accurate system for both routine and high-performance analyses,” said Jonathan Rennert, vice president and general manager, Analytical Sciences, for PerkinElmer’s Life and Analytical Sciences division. “The introduction of the Clarus 600 GC/MS demonstrates our commitment to the GC market, offering reliable performance for a variety of markets and applications – including the environmental market need for high sample throughput of volatile and semivolatile samples.”
Rennert noted that while other manufacturers OEM or partner to provide a complete system, PerkinElmer is unique in offering customers a single source for a complete and fully integrated system based on their performance and throughput requirements. “Customers will have added confidence because all of the integrated components of a complete GC/MS system, from sample handling through separation, detection and data handling to results are developed, manufactured, tested and serviced by PerkinElmer to ensure that the system optimally works together,” Rennert said.
The Clarus 600 MS, combined with the new Clarus 600 GC powered by the best-in-class oven, is designed for a variety of laboratory requirements to ensure increased throughput and improved detection limits and to provide significant return on investment.
Hardware improvements include best-in-class oven performance with state-of-the-art electronics, providing fast scanning and increased productivity, multiple pumping options to meet every lab’s needs, a compact footprint to maximize laboratory bench space, the PreVent suite of column flow controls for increased uptime and productivity, and industry-leading sensitivity for both electron ionization (EI) and chemical ionization (CI). The new PerkinElmer TurboMass™ 5.3 GC/MS software assures method compliance and increased laboratory productivity with expanded resources for the updated electronics and pumping options. This software also includes the latest tools for data evaluation with flexible reporting capabilities for a variety of environmental requirements. More than 70 standard report templates and many other significant software tools are built in such as SIFI™ (simultaneous collection of Selected Ion and Full Ion scanning). TurboMass software uses a sample-centric architecture requiring only two clicks to view the mass spectrum or other information collected on a sample, and advanced noise-reduction algorithms as well as other tools for complex analyses.
Featured at Upcoming Trade Shows
The Clarus 600 GC/MS will be among the PerkinElmer products on display at upcoming trade shows including: National Environmental Monitoring Conference (NEMC), Aug. 28-31, 2006, Washington D.C.; JAIMA, Aug. 30-Sept. 1, 2006, Chiba, Japan; AnalyticaChina, Sept. 19-21, 2006, Shanghai, China; ScanLab 2006, Sept. 26-28, 2006, Copenhagen, Denmark; HET Instrument, Oct. 30-Nov. 3, 2006, Utrecht, Netherlands; and Analytica-Anacon, Nov. 16-18, 2006, Bangalore, India.
For more information on the Clarus 600 GC/MS visit www.perkinelmer.com/Clarus600GCMS.
Factors Affecting Future Performance
This press release contains 'forward-looking' statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as 'believes,' 'intends,' 'anticipates,' 'plans,' 'expects,' “projects,” “forecasts,” 'will' and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.